Specializing In:
- Hematopathology
- Bone marrow and lymph node examination
- Flow cytometry
- Immunohistochemistry
- Molecular diagnostics
Research Interests:
- Initiation and progression of hematolymphoid neoplasms
Biography
Positions
Roswell Park Comprehensive Cancer Center
- Professor of Oncology
- Vice Chair, Hematopathology
- Department of Pathology & Laboratory Medicine
Background
Education and Training
- 2004 - PhD - Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL
- 1994 - MD - Medicine, University of Medicine and Pharmacy of Targu-Mures, Romania
Residency
- 2001-2005 - Anatomic and Clinical Pathology, University of Alabama at Birmingham, Birmingham, AL
Fellowship
- 2005-2006 - Hematopathology, University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX
- 2006-2007 - Advanced Hematopathology, University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX
Board Certification
- Anatomic and Clinical Pathology - American Board of Pathology
- Hematology (Pathology) - American Board of Pathology
- Clinical Informatics - American Board of Pathology
Professional Memberships
- USCAP
- ASCP
- CAP
- SH
Professional Experience
- 2007-2024 - Staff, Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH
Publications
1. Formalin Fixation Followed by Paraffin Embedding Allows Long-Term Storage of Proteins for Liquid Chromatography-Tandem Mass Spectrometry Analysis.
Feldiorean A, Bena J, Nakashima MO, McShane AJ, Cotta CV.
Lab Invest. 2023 Oct;103(10):100224. doi: 10.1016/j.labinv.2023.100224. Epub 2023 Jul 28.
2. Nodular pulmonary light chain deposition disease: an entity associated with Sjögren syndrome or marginal zone lymphoma.
Arrossi AV, Merzianu M, Farver C, Yuan C, Wang SH, Nakashima MO, Cotta CV.
J Clin Pathol. 2016 Jun;69(6):490-6. doi: 10.1136/jclinpath-2015-203342. Epub 2015 Oct 26.
3. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site.
Cotta CV, Coleman JF, Li S, Hsi ED.
Histopathology. 2011 Dec;59(6):1194-203. doi: 10.1111/j.1365-2559.2011.04054.x.
4. The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors.
Theil KS, Cotta CV.
Cancer Genet. 2014 May;207(5):171-6. doi: 10.1016/j.cancergen.2014.05.006. Epub 2014 May 21.
5. Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development.
Cotta CV, Zhang Z, Kim HG, Klug CA.
Blood. 2003 Jun 1;101(11):4342-6. doi: 10.1182/blood-2002-10-3139. Epub 2003 Jan 30.
6. Patients with Classic Hodgkin Lymphoma and Follicular Lymphoma Compared to Single Malignancy Controls.
Cotta CV, Bhavsar S, Robertson S, Cook JR.
Am J Surg Pathol. 2024 Aug 1;48(8):965-971. doi: 10.1097/PAS.0000000000002225. Epub 2024 Apr 11.